endpoint missed in pivotal phase III study in patients with acute moderate-to-severe pain following orthopedic surgery (8/09); despite documented efficacy, there are still safety concerns about drug abuse and its well-documented hallucinatory effects (2/10)
Brand Ereska Generic ketamine (PMI-150)
Company name Javelin Product type Non-speciality
Therapeutic category CNS Key uses pain management
Other Uses N/A Drug Class N-methyl-D-aspartate (NMDA) receptor antagonist (non-opiate)
Dosage From nasal spray Expected Approval 2012+
FDA Filing N/A Last Update date June 01,2010
Link to pipeline report
Link to news article
Link to clinicaltrials.gov
Link to press releases